HIV. Penetration of tenofovir and emtricitabine in mucosal tissues: Implications for prevention of HIV-1 transmission

Science Translational Medicine

Volumn 3, Issue 112, 2011, Pages

  Patterson, Kristine B ^a   Prince, Heather A ^a   Kraft, Eric ^b,d   Jenkins, Amanda J ^b,e   Shaheen, Nicholas J ^a   Rooney, James F ^c   Cohen, Myron S ^a   Kashuba, Angela D M ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina   (United States)

^c GILEAD SCIENCES   (United States)

^d GLAXOSMITHKLINE   (United States)

^e UNITED THERAPEUTICS CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; TENOFOVIR DISOPROXIL; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG PENETRATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; INFECTION PREVENTION; MALE; PRIORITY JOURNAL; RECTUM MUCOSA; SEMINAL PLASMA; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SEXUAL BEHAVIOR; SINGLE DRUG DOSE; UTERINE CERVIX MUCOSA; VAGINA MUCOSA; VIRUS TRANSMISSION; ADOLESCENT; DISEASE TRANSMISSION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

ADENINE; ADOLESCENT; ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; DEOXYCYTIDINE; FEMALE; HIV INFECTIONS; HUMANS; MALE; PHOSPHONIC ACIDS;

EID: 83155177076     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003174     Document Type: Article

References (33)

1. UNAIDS Report on the Global AIDS Epidemic 2010; http://www.unaids.org/ documents/20101123-GlobalReport-em.pdf [accessed 14 December 2010].
2. D. Donnell, J. M. Baeten, J. Kiarie, K. K. Thomas,W. Stevens, C. R. Cohen, J. McIntyre, J. R. Lingappa, C. Celum; Partners in Prevention HSV/HIV Transmission Study Team, Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: A prospective cohort analysis. Lancet 375, 2092-2098 (2010).
3. Panel on the Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1 Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States, 24 May 2010, pp. 1-117; http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx [accessed 14 December 2010].
4. Q. Abdool Karim, S. S. Abdool Karim, J. A. Frohlich, A.C. Grobler, C. Baxter, L. E. Mansoor, A. B. Kharsany, S. Sibeko, K. P. Mlisana, Z. Omar, T. N. Gengiah, S. Maarschalk, N. Arulappan, M. Mlotshwa, L. Morris, D. Taylor; CAPRISA 004 Trial Group, Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329, 1168-1174 (2010).
5. R. M. Grant, J. R. Lama, P. L. Anderson, V. McMahan, A. Y. Liu, L. Vargas, P. Goicochea, M. Casapía, J. V. Guanira-Carranza, M. E. Ramirez-Cardich, O. Montoya-Herrera, T. Fernández, V. G. Veloso, S. P. Buchbinder, S. Chariyalertsak, M. Schechter, L. G. Bekker, K. H. Mayer, E. G. Kallás, K. R. Amico, K. Mulligan, L. R. Bushman, R. J. Hance, C. Ganoza, P. Defechereux, B. Postle, F. Wang, J. J. McConnell, J. H. Zheng, J. Lee, J. F. Rooney, H. S. Jaffe, A. I. Martinez, D. N. Burns, D. V. Glidden; iPrEx Study Team, Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363, 2587-2599 (2010).
6. A. Kashuba, S. S. Abdool Karim, E. Kraft, N. White, S. Sibeko, L. Werner, L. Mansoor, T. Gengiah, S. Sidhoo, V. Naranbhai, Q. Abdool Karim, Do systemic and genital tract tenofovir concentrations predict HIV seroconversion in the CAPRISA 004 tenofovir gel trial?, paper presented at the XVIII International AIDS Conference, Vienna, Austria, 18 to 23 July 2010.
7. P. Anderson, J. Lama, S. Buchbinder, J. Guanira, O. Montoya, M. Casapia, L. Bragg, L. Bushman, D. Glidden, R. Grant, Interpreting detection rates of intracellular FTC-TP and TFV-DP: The iPrEx trial, paper presented at the 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 27 February to 2 March 2011.
8. M. Thigpen, P. Kebaabetswe, D. Smith, T. Segolodi, F. Soud, K. Chillag, L. I. Chirwa, M. Kasonde, R. Mutanhaurwa, F. L. Henderson, S. Pathak, R. Gvetadze, C. E. Rose, L. A. Paxton, Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: Results from the TDF2 study, paper presented at the 6th International AIDS Society Conference, Rome, Italy, 17 to 20 July 2011.
9. J. Baeton, C. Celum, Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: The Partners PrEP Study, paper presented at the 6th International AIDS Society Conference, Rome, Italy, 17 to 20 July 2011.
10. FHI360. FEM-PrEP Project; http://www.fhi.org/en/Research/Projects/FEM- PrEP.htm [accessed 2 August 2011].
11. NIH modifies 'VOICE' HIV prevention study in women; http://www.nih.gov/ news/health/sep2011/niaid-28.htm [accessed 6 October 2011].
12. M. R. Blum, G. E. Chittick, J. A. Begley, J. Zong, Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J. Clin. Pharmacol. 47, 751-759 (2007).
13. J. B. Dumond, R. F. Yeh, K. B. Patterson, A. H. Corbett, B. H. Jung, N. L. Rezk, A. S. Bridges, P. W. Stewart, M. S. Cohen, A. D. Kashuba, Antiretroviral drug exposure in the female genital tract: Implications for oral pre- and post-exposure prophylaxis. AIDS 21, 1899-1907 (2007).
14. M. S. Cohen, C. Gay, A. D. Kashuba, S. Blower, L. Paxton, Narrative review: Antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann. Intern. Med. 146, 591-601 (2007).
15. J. G. García-Lerma, R. A. Otten, S. H. Qari, E. Jackson, M. E. Cong, S. Masciotra, W. Luo, C. Kim, D. R. Adams, M. Monsour, J. Lipscomb, J. A. Johnson, D. Delinsky, R. F. Schinazi, R. Janssen, T. M. Folks, W. Heneine, Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 5, e28 (2008).
16. S. Subbarao, A. Ramos, C. Kim, D. Adams, M. Monsour, S. Butera, T. Folks, R. A. Otten, Direct stringency comparison of two macaque models (single-high vs. repeat-low) for mucosal HIV transmission using an identical anti-HIV chemoprophylaxis intervention. J. Med. Primatol. 36, 238-243 (2007).
17. R. S. Veazey, P. J. Klasse, S. M. Schader, Q. Hu, T. J. Ketas, M. Lu, P. A. Marx, J. Dufour, R. J. Colonno, R. J. Shattock, M. S. Springer, J. P. Moore, Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438, 99-102 (2005).
18. J. G. García-Lerma, M. E. Cong, J. Mitchell, A. S. Youngpairoj, Q. Zheng, S. Masciotra, A. Martin, Z. Kuklenyik, A. Holder, J. Lipscomb, C. P. Pau, J. R. Barr, D. L. Hanson, R. Otten, L. Paxton, T. M. Folks, W. Heneine, Intermittent prophylaxis with oral Truvada protects macaques from rectal SHIV infection. Sci. Transl. Med. 2, 14ra4 (2010).
19. Y. Ganor, M. Bomsel, HIV-1 transmission in the male genital tract. Am. J. Reprod. Immunol. 65, 284-291 (2011).
20. N. A. Gomes, A. Laud, A. Pudage, S. S. Joshi, V. V. Vaidya, J. A. Tandel, Validated LC-MS/MS method for determination of Alverine and one of its hydroxy metabolites in human plasma along with its application to a bioequivalence study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877, 197-206 (2009).
21. A. D'Avolio, M. Sciandra, M. Siccardi, L. Baietto, D. Gonzalez de Requena, S. Bonora, G. Di Perri, A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients. J. Chromatogr. Sci. 46, 524-528 (2008).
22. M. Vourvahis, H. L. Tappouni, K. B. Patterson, Y. C. Chen, N. L. Rezk, S. A. Fiscus, B. P. Kearney, J. F. Rooney, J. Hui, M. S. Cohen, A. D. Kashuba, The pharmacokinetics and viral activity of tenofovir in the male genital tract. J. Acquir. Immune Defic. Syndr. 47, 329-333 (2008).
23. Gilead Sciences, TRUVADA (emtricitabine/tenofovir disoproxil fumarate) tablets package insert (Gilead Sciences, Foster City, CA, 2009).
24. T. Hawkins, W. Veikley, R. L. St Claire III, B. Guyer, N. Clark, B. P. Kearney, Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J. Acquir. Immune Defic. Syndr. 39, 406-411 (2005).
25. K. B. Patterson, H. A. Prince, E. Kraft, A. Jones, S. Paul, N. J. Shaheen, M. Spacek, P. E. Heidt, S. Reddy, J. F. Rooney, J. B. Dumond, M. S. Cohen, A. D. Kashuba, Exposure of extracellular and intracellular tenofovir and emtricitabine in mucosal tissues after a single of fixed-dose TDF/FTC: Implications for pre-exposure HIV prophylaxis, paper presented at the XVIII International AIDS Conference, Vienna, Austria, 18 to 23 July 2010.
26. P. Anton, R. Cranston, A. Carballo-Diegue, A. Kashuba, E. Khanukhova, J. Elliott, L. Janocko, W. Cumberland, C. Mauck, I. McGowan, RMP-02/MTN-006: A phase 1 placebo-controlled trial of rectally applied 1% vaginal TFV gel with comparison to oral TDF, paper presented at the 18th Conference on Retrovirus and Opportunistic Infections, Boston, MA, 28 February to 2 March 2011.
27. C. Hendrix, A. Minnis, V. Guddera, S. Riddler, R. Salata, C. Nakabiito, C. Hoesley, J. Justman, L. Soto-Torres, B. Richardson, MTN-001: A phase 2 cross-over study of daily oral and vaginal TFV in healthy, sexually active women results in significantly different product acceptability and vaginal tissue drug concentrations, paper presented at the 18th Conference on Retrovirus and Opportunistic Infections, Boston, MA, 28 February to 2 March 2011.
28. P. W. Denton, J. D. Estes, Z. Sun, F. A. Othieno, B. L. Wei, A. K. Wege, D. A. Powell, D. Payne, A. T. Haase, J. V. Garcia, Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 5, e16 (2008).
29. S. Subbarao, R. A. Otten, A. Ramos, C. Kim, E. Jackson, M. Monsour, D. R. Adams, S. Bashirian, J. Johnson, V. Soriano, A. Rendon, M. G. Hudgens, S. Butera, R. Janssen, L. Paxton, A. E. Greenberg, T. M. Folks, Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J. Infect. Dis. 194, 904-911 (2006).
30. M. S. Cohen, G. M. Shaw, A. J. McMichael, B. F. Haynes, Acute HIV-1 infection. N. Engl. J. Med. 364, 1943-1954 (2011).
31. S. S. Karim, A. D. Kashuba, L. Werner, Q. A. Karim, Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: Implications for HIV prevention in women. Lancet 378, 279-281 (2011).
32. A. Kwara, A. DeLong, N. Rezk, J. Hogan, H. Burtwell, S. Chapman, C. C. Moreira, J. Kurpewski, J. Ingersoll, A. M. Caliendo, A. Kashuba, S. Cu-Uvin, Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active anti-retroviral therapy. Clin. Infect. Dis. 46, 719-725 (2008).
33. G. Mardirossian, M. Tagesson, P. Blanco, L. G. Bouchet, M. Stabin, H. Yoriyaz, S. Baza, M. Ljungberg, S. E. Strand, A. B. Brill, A new rectal model for dosimetry applications. J. Nucl. Med. 40, 1524-1531 (1999).